Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17507218rdf:typepubmed:Citationlld:pubmed
pubmed-article:17507218lifeskim:mentionsumls-concept:C0030193lld:lifeskim
pubmed-article:17507218lifeskim:mentionsumls-concept:C0026336lld:lifeskim
pubmed-article:17507218lifeskim:mentionsumls-concept:C0041942lld:lifeskim
pubmed-article:17507218lifeskim:mentionsumls-concept:C0332255lld:lifeskim
pubmed-article:17507218lifeskim:mentionsumls-concept:C0333348lld:lifeskim
pubmed-article:17507218lifeskim:mentionsumls-concept:C1421467lld:lifeskim
pubmed-article:17507218lifeskim:mentionsumls-concept:C0243076lld:lifeskim
pubmed-article:17507218lifeskim:mentionsumls-concept:C0201734lld:lifeskim
pubmed-article:17507218lifeskim:mentionsumls-concept:C1999230lld:lifeskim
pubmed-article:17507218lifeskim:mentionsumls-concept:C0871161lld:lifeskim
pubmed-article:17507218pubmed:issue14lld:pubmed
pubmed-article:17507218pubmed:dateCreated2007-6-22lld:pubmed
pubmed-article:17507218pubmed:abstractTextSAR studies for N-aryl-N'-benzyl urea class of TRPV1 antagonists have been extended to cover alpha-benzyl alkylation. Alkylated compounds showed weaker in vitro potencies in blocking capsaicin activation of TRPV1 receptor, but possessed improved pharmacokinetic properties. Further structural manipulations that included replacement of isoquinoline core with indazole and isolation of single enantiomer led to TRPV1 antagonists like (R)-16a with superior pharmacokinetic properties and greater potency in animal model of inflammatory pain.lld:pubmed
pubmed-article:17507218pubmed:languageenglld:pubmed
pubmed-article:17507218pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17507218pubmed:citationSubsetIMlld:pubmed
pubmed-article:17507218pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17507218pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17507218pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17507218pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17507218pubmed:statusMEDLINElld:pubmed
pubmed-article:17507218pubmed:monthJullld:pubmed
pubmed-article:17507218pubmed:issn0960-894Xlld:pubmed
pubmed-article:17507218pubmed:authorpubmed-author:HonorePriscaPlld:pubmed
pubmed-article:17507218pubmed:authorpubmed-author:MarshKennan...lld:pubmed
pubmed-article:17507218pubmed:authorpubmed-author:McDonaldHeath...lld:pubmed
pubmed-article:17507218pubmed:authorpubmed-author:MikusaJoeJlld:pubmed
pubmed-article:17507218pubmed:authorpubmed-author:LeeChih-HungC...lld:pubmed
pubmed-article:17507218pubmed:authorpubmed-author:DrizinIreneIlld:pubmed
pubmed-article:17507218pubmed:authorpubmed-author:GomtsyanArthu...lld:pubmed
pubmed-article:17507218pubmed:authorpubmed-author:DidomenicoSta...lld:pubmed
pubmed-article:17507218pubmed:authorpubmed-author:FaltynekConni...lld:pubmed
pubmed-article:17507218pubmed:authorpubmed-author:SurowyCarol...lld:pubmed
pubmed-article:17507218pubmed:authorpubmed-author:BayburtErol...lld:pubmed
pubmed-article:17507218pubmed:authorpubmed-author:TurnerSean...lld:pubmed
pubmed-article:17507218pubmed:authorpubmed-author:KoenigJohn...lld:pubmed
pubmed-article:17507218pubmed:authorpubmed-author:PernerRichard...lld:pubmed
pubmed-article:17507218pubmed:authorpubmed-author:WetterJill...lld:pubmed
pubmed-article:17507218pubmed:authorpubmed-author:JinkersonTamm...lld:pubmed
pubmed-article:17507218pubmed:authorpubmed-author:KeddyRyanRlld:pubmed
pubmed-article:17507218pubmed:issnTypePrintlld:pubmed
pubmed-article:17507218pubmed:day15lld:pubmed
pubmed-article:17507218pubmed:volume17lld:pubmed
pubmed-article:17507218pubmed:ownerNLMlld:pubmed
pubmed-article:17507218pubmed:authorsCompleteYlld:pubmed
pubmed-article:17507218pubmed:pagination3894-9lld:pubmed
pubmed-article:17507218pubmed:meshHeadingpubmed-meshheading:17507218...lld:pubmed
pubmed-article:17507218pubmed:meshHeadingpubmed-meshheading:17507218...lld:pubmed
pubmed-article:17507218pubmed:meshHeadingpubmed-meshheading:17507218...lld:pubmed
pubmed-article:17507218pubmed:meshHeadingpubmed-meshheading:17507218...lld:pubmed
pubmed-article:17507218pubmed:meshHeadingpubmed-meshheading:17507218...lld:pubmed
pubmed-article:17507218pubmed:meshHeadingpubmed-meshheading:17507218...lld:pubmed
pubmed-article:17507218pubmed:meshHeadingpubmed-meshheading:17507218...lld:pubmed
pubmed-article:17507218pubmed:meshHeadingpubmed-meshheading:17507218...lld:pubmed
pubmed-article:17507218pubmed:meshHeadingpubmed-meshheading:17507218...lld:pubmed
pubmed-article:17507218pubmed:year2007lld:pubmed
pubmed-article:17507218pubmed:articleTitleAlpha-methylation at benzylic fragment of N-aryl-N'-benzyl ureas provides TRPV1 antagonists with better pharmacokinetic properties and higher efficacy in inflammatory pain model.lld:pubmed
pubmed-article:17507218pubmed:affiliationGlobal Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064, USA. arthur.r.gomtsyan@abbott.comlld:pubmed
pubmed-article:17507218pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:17507218lld:chembl